Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors

An important issue in allogeneic peripheral blood progenitor cell transplantation is the optimization of the regimen of mobilization of progenitor cells from normal donors. It has been shown that for G-CSF doses up to 10 μg/kg/day, a dose–response relationship exists for the degree of progenitor cell mobilization. Formal comparisons with doses higher than 10 μg/kg/day, however, have not been reported. The aim of this study was to compare the mobilization and collection results of two different G-CSF (Filgrastim) schedules: 10 μg/kg/12 h (n = 20; group A) vs 10 μg/kg/24 h (n = 20; group B). Apheresis sessions were started on day 5 (after 4 days of G-CSF). Adverse events consisted of bone pain, headache, and fatigue which required treatment with acetaminophen ± codeine in both donor groups. Discontinuation of G-CSF administration for intolerable side-effects was not necessary in any case. The increase in peripheral leukocyte and lymphocyte counts × 109/l on day 5 was higher in group A (56.2 (37.1–75.2) and 4.4 (2.1–14.6), respectively) than in group B (27.5 (13.2–53.9) and 2.6 (1.9–5.1), respectively) (P < 0.0001 and P = 0.008). Platelets × 109/l decreased in group A from 228 (161–286) before G-CSF administration to 207 (155–328) on day 5 (P = 0.03), whereas no change was observed in group B. Following the first apheresis, a significant decrease in platelet count was observed with both G-CSF schedules without any differences between groups. The number × 106/kg of both nucleated and CD34+ cells collected after the first apheresis session was higher in group A (672 (462–992) and 5.9 (3.4–10.4), respectively) than in group B (427 (319–608) and 3.1 (1.1–6.8), respectively) (P = 0.0003 in both cases). The median number of CD3+cells × 106/kg collected after one apheresis session was similar with both G-CSF schedules (212 (91–430) in group A and 170 (110–291) in group B) (P = NS). In conclusion, the schedule of 10 μg/kg/12 h was well tolerated and resulted in the collection of a higher number of progenitor cells than 10 μg/kg/24 h without increasing the T cell content. This approach could avoid the donor having to undergo a second apheresis, and facilitate further graft manipulation.

[1]  J. Briones,et al.  Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors , 1996, Annals of Hematology.

[2]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[3]  B. Andersson,et al.  Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. , 1996, Bone marrow transplantation.

[4]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[5]  A. Santoro,et al.  Mobilization and collection of PBSC in healthy donors: comparison between two schemes of rhG‐CSF administration , 1996, European journal of haematology.

[6]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[7]  D. Linch,et al.  Optimal timing for collection of PBPC after glycosylated G-CSF administration , 1998, Bone Marrow Transplantation.

[8]  R. Champlin,et al.  Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. , 1996, Blood.

[9]  R. Champlin,et al.  Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.

[10]  C. Dunbar,et al.  CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies , 1996 .

[11]  J. Goldman Peripheral blood stem cells for allografting. , 1995, Blood.

[12]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[13]  J. Doroshow,et al.  Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. , 1997, Blood.

[14]  T. Tötterman,et al.  Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. , 1996, Bone marrow transplantation.

[15]  R Storb,et al.  The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. , 1993, Blood.

[16]  L Davies,et al.  Bone marrow transplant. , 1985, Nursing times.

[17]  P. Anderlini,et al.  Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis , 1996, British journal of haematology.

[18]  G. Bernini,et al.  G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective , 1998, Bone Marrow Transplantation.

[19]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.

[20]  B. McAneny,et al.  Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.

[21]  F. Benvenuto,et al.  Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.

[22]  N. Kröger,et al.  Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg) , 1999, Bone Marrow Transplantation.

[23]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.